Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

Abstract excerpt

Most academic precision oncology programs have been designed to facilitate enrollment of patients in early clinical trials with matched targeted agents. Over the last decade, major changes were seen both in the targetable molecular alteration landscape and in drug development trends. In this article, we describe how the Vall d’Hebron Institute of Oncology molecular prescreening program adapted to a dynamic model...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to CAR-T cell therapy research
• Share to Pancreatic and Hepatic Oncology Research